These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
64 related articles for article (PubMed ID: 1963137)
1. [The behavior of unfractionated and low-molecular heparin in the body of the rat]. Khlgatian SV; Umarova BA; Sahpiro FB; Strukova SM Dokl Akad Nauk SSSR; 1990; 313(2):509-11. PubMed ID: 1963137 [No Abstract] [Full Text] [Related]
2. [Comparative pharmacokinetic study, in the dog, of low molecular weight heparin and standard heparin by labelling with 35S]. Uzan A; Marin J; Mardiguian J; Trillou M; Kiosseff T; Rougeot C Ann Pharm Fr; 1987; 45(6):429-37. PubMed ID: 2847624 [No Abstract] [Full Text] [Related]
3. [The incorporation of 35S-heparin into mast cells in the rat and its release into the circulatory bed]. Umarova BA; Shapiro FB; Khlgatian SV; Strukova SM Biull Eksp Biol Med; 1989 Dec; 108(12):648-51. PubMed ID: 2634431 [TBL] [Abstract][Full Text] [Related]
4. [The dynamics of the body distribution of heparin and its antagonist, the quaternary ammonium salt of conidine oligomer-25, when administered via the lungs]. Rumiantsev AG; Golovleva OA; Rozkin MIa; Kazarian VA; Efimov VS Farmakol Toksikol; 1991; 54(1):49-51. PubMed ID: 1860499 [TBL] [Abstract][Full Text] [Related]
5. [The reaction of the mast cell population to the intratracheal administration of heparin and fucoidan]. Rumiantseva AG; Kotel'nikov VM; Rozkin MIa; Efimov VS Biull Eksp Biol Med; 1991 Nov; 112(11):507-9. PubMed ID: 1810490 [TBL] [Abstract][Full Text] [Related]
6. Kinetics of radiolabelled (99mTc) heparin and low molecular weight heparin fractions CY 216, CY 222 in patients with uncomplicated myocardial infarction. Psuja P Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(5):661-8. PubMed ID: 2465247 [TBL] [Abstract][Full Text] [Related]
7. [Anticoagulant and antithrombotic effects of low molecular weight heparin]. Bashkov GV; Kalishevskaia TM; Bako N Biull Eksp Biol Med; 1988 Oct; 106(10):399-402. PubMed ID: 2847825 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic studies of standard unfractionated heparin, and low molecular weight heparins in the rabbit. Boneu B; Caranobe C; Cadroy Y; Dol F; Gabaig AM; Dupouy D; Sie P Semin Thromb Hemost; 1988 Jan; 14(1):18-27. PubMed ID: 3353731 [No Abstract] [Full Text] [Related]
10. Pharmacodynamics of unfractionated heparin during and after a hemodialysis session: the impact of the administered dose. Fourtounas C Am J Kidney Dis; 2008 Oct; 52(4):805-6; author reply 806-7. PubMed ID: 18805352 [No Abstract] [Full Text] [Related]
11. Complexes of a modified low-molecular-weight heparin with protamine are predominantly cleared by a macrophage scavenger receptor-mediated process in rats. Stehle G; Wunder A; Sinn H; Schrenk HH; Friedrich EA; Dempfle CE; Maier-Borst W; Heene DL J Surg Res; 1995 Feb; 58(2):197-204. PubMed ID: 7861773 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of heparin and low molecular weight heparin fragment (Fragmin) in rabbits with impaired renal or metabolic clearance. Palm M; Mattsson C Thromb Haemost; 1987 Oct; 58(3):932-5. PubMed ID: 2829379 [TBL] [Abstract][Full Text] [Related]
13. Altered pharmacokinetic properties of a lipophilically derivatized low-molecular-weight heparin in rats. Stehle G; Sinn H; Friedrich EA; Wunder A; Schrenk HH; Harenberg J; Peschke P; Dempfle CE; Maier-Borst W; Heene DL J Lab Clin Med; 1993 Dec; 122(6):728-38. PubMed ID: 8245692 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and organ distribution in rats of a low molecular weight heparin. Guizzardi S; Mastacchi R; Govoni P; Milani MR; Barbanti M; Ruggeri A Arzneimittelforschung; 1987 Nov; 37(11):1281-3. PubMed ID: 2830892 [TBL] [Abstract][Full Text] [Related]
15. Unfractionated heparin, low molecular weight heparins, and pentasaccharide: basic mechanism of actions, pharmacology, and clinical use. Bick RL; Frenkel EP; Walenga J; Fareed J; Hoppensteadt DA Hematol Oncol Clin North Am; 2005 Feb; 19(1):1-51, v. PubMed ID: 15639107 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of low molecular weight heparin and unfractionated heparin in pregnancy. Ensom MH; Stephenson MD J Soc Gynecol Investig; 2004 Sep; 11(6):377-83. PubMed ID: 15350250 [TBL] [Abstract][Full Text] [Related]
17. Is establishing an appropriate bleeding risk profile in elderly patients treated with low-molecular-weight heparins needed? Anton E; Marti J J Am Geriatr Soc; 2005 Oct; 53(10):1834-5; author reply 1835-6. PubMed ID: 16181193 [No Abstract] [Full Text] [Related]
18. Pharmacokinetic and pharmacodynamic characterization of a medium-molecular-weight heparin in comparison with UFH and LMWH. Alban S; Welzel D; Hemker HC Semin Thromb Hemost; 2002 Aug; 28(4):369-78. PubMed ID: 12244484 [TBL] [Abstract][Full Text] [Related]
19. Effects of low-molecular-weight and unfractionated heparin on trophoblast function. Quenby S; Mountfield S; Cartwright JE; Whitley GS; Vince G Obstet Gynecol; 2004 Aug; 104(2):354-61. PubMed ID: 15292011 [TBL] [Abstract][Full Text] [Related]
20. A reduction in accelerated graft coronary disease and an improvement in cardiac allograft survival using low molecular weight heparin in combination with cyclosporine. Aziz S; Tada Y; Gordon D; McDonald TO; Fareed J; Verrier ED J Heart Lung Transplant; 1993; 12(4):634-43. PubMed ID: 8396435 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]